1 |
Johnston SD, Root Kustritz MV, Olson PNS. 2001. Canine and Feline Theriogenology. Saunders, Philadelphia, pp. 337-341.
|
2 |
Nizanski W, Levy X, Ochota M, Pasikowska J. 2014. Pharmacological treatment for common prostatic conditions in dogs - benign prostatic hyperplasia and prostatitis: an update. Reprod. Domest. Anim. 49 Suppl 2:8-15.
DOI
|
3 |
Angrimani DSR, Brito MM, Rui BR, Nichi M, Vannucchi CI. 2020. Reproductive and endocrinological effects of Benign Prostatic Hyperplasia and finasteride therapy in dogs. Sci. Rep. 10:14834.
DOI
|
4 |
Cohen SM, Werrmann JG, Rasmusson GH, Tanaka WK, Malatesta PF, Prahalada S, Jacobs JG, Harris G, Nett TM. 1995. Comparison of the effects of new specific azasteroid inhibitors of steroid 5 alpha-reductase on canine hyperplastic prostate: suppression of prostatic DHT correlated with prostate regression. Prostate 26:55-71.
DOI
|
5 |
Laroque PA, Prahalada S, Molon-Noblot S, Cohen SM, Soper K, Duprat P, Peter CP, van Zwieten MJ. 1995. Quantitative evaluation of glandular and stromal compartments in hyperplastic dog prostates: effect of 5-alpha reductase inhibitors. Prostate 27:121-128.
DOI
|
6 |
Lowseth LA, Gerlach RF, Gillett NA, Muggenburg BA. 1990. Age-related changes in the prostate and testes of the beagle dog. Vet. Pathol. 27:347-353.
DOI
|
7 |
Peters DH and Sorkin EM. 1993. Finasteride. A review of its potential in the treatment of benign prostatic hyperplasia. Drugs 46:177-208.
DOI
|
8 |
Selman SH. 2011. The McNeal prostate: a review. Urology 78:1224-1228.
DOI
|
9 |
Sirinarumitr K, Sirinarumitr T, Johnston SD, Sarkar DK, Kustritz MV. 2002. Finasteride-induced prostatic involution by apoptosis in dogs with benign prostatic hypertrophy. Am. J. Vet. Res. 63:495-498.
DOI
|